Who are AZD9291's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ASKC202+ Limertinib, Firmonertinib Mesilate Tablets, Furmonertinib Mesilate Tablets, SHR-A2009 ; Aumolertinib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd9291.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

AZD9291 — Competitive Intelligence Brief

AZD9291 (AZD9291) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Third-generation EGFR tyrosine kinase inhibitor. Area: Oncology.

phase 3 Third-generation EGFR tyrosine kinase inhibitor EGFR (Epidermal Growth Factor Receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD9291 (AZD9291) — Soroka University Medical Center. AZD9291 is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to mutant EGFR while sparing wild-type EGFR, overcoming resistance from the T790M mutation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD9291 TARGET	AZD9291	Soroka University Medical Center	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor)
ASKC202+ Limertinib	ASKC202+ Limertinib	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	phase 3	Bispecific antibody + third-generation EGFR tyrosine kinase inhibitor combination	EGFR (epidermal growth factor receptor) and c-MET (mesenchymal-epithelial transition factor)
Firmonertinib Mesilate Tablets	Firmonertinib Mesilate Tablets	Allist Pharmaceuticals, Inc.	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor)
Furmonertinib Mesilate Tablets	Furmonertinib Mesilate Tablets	Allist Pharmaceuticals, Inc.	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
SHR-A2009 ; Aumolertinib	SHR-A2009 ; Aumolertinib	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Third-generation EGFR tyrosine kinase inhibitor	EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Third-generation EGFR tyrosine kinase inhibitor class)

Allist Pharmaceuticals, Inc. · 2 drugs in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 1 drug in this class
Soroka University Medical Center · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD9291 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9291. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab